khellin has been researched along with Cirrhosis in 87 studies
Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024)
khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Keloid fibroblasts were cultured and exposed to different concentrations of troglitazone in the presence of TGF-beta1." | 7.75 | Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts. ( Chen, XL; Gao, WY; Guo, SZ; Li, X; Li, ZJ; Ma, B; Yi, CG; Zhang, GY, 2009) |
| "Keloids are characterized by increased deposition of fibrous tissue in the skin and subcutaneous tissue following an abnormal wound healing process." | 5.62 | Halofuginone regulates keloid fibroblast fibrotic response to TGF-β induction. ( Chatelain, B; Dirand, Z; Humbert, P; Isidoro, C; Lihoreau, T; Marty, P; Rolin, G; Secomandi, E; Senez, C; Tissot, M, 2021) |
| "Keloid and hypertrophic scars are skin fibrosis-associated disorders that exhibit an uncontrollable proliferation of fibroblasts and their subsequent contribution to the excessive accumulation of extracellular matrix (ECM) in the dermis." | 5.62 | Ameliorating Fibrotic Phenotypes of Keloid Dermal Fibroblasts through an Epidermal Growth Factor-Mediated Extracellular Matrix Remodeling. ( Anggradita, LD; Bae, J; Hur, SS; Hwang, NS; Hwang, Y; Kim, H; Lee, SJ; Nam, SM, 2021) |
| "Paclitaxel (PTX) was an effective chemotherapeutic agent and has been reported to have anti-fibrotic effects, but the strong hydrophobicity brings a challenge for its clinical application." | 5.51 | Improving the anti-keloid outcomes through liposomes loading paclitaxel-cholesterol complexes. ( Chen, L; Gao, Z; Huang, W; Jin, M; Jin, Z; Wang, M; Wang, Q, 2019) |
| "Ginsenoside Rg3 (Rg3) has been reported to exert numerous antitumor effects, thus indicating that Rg3 may be a potential therapeutic agent that targets keloids." | 5.48 | Ginsenoside Rg3 inhibits keloid fibroblast proliferation, angiogenesis and collagen synthesis in vitro via the TGF‑β/Smad and ERK signaling pathways. ( Bian, W; Cheng, L; Jin, R; Tang, M; Wang, W; Zhang, L; Zhang, Y, 2018) |
| "Keloids are wounding-induced tumor-like human scars." | 5.43 | Keloid-derived, plasma/fibrin-based skin equivalents generate de novo dermal and epidermal pathology of keloid fibrosis in a mouse model. ( Benya, PD; Chiu, WC; Choi, A; Hsu, T; Kim, EW; Kulber, DA; Lee, YS; Sarkozy, H; Tuan, TL, 2016) |
| "Keloid fibroblasts were cultured and exposed to different concentrations of troglitazone in the presence of TGF-beta1." | 3.75 | Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts. ( Chen, XL; Gao, WY; Guo, SZ; Li, X; Li, ZJ; Ma, B; Yi, CG; Zhang, GY, 2009) |
| "Fibrosis is characterized by an excessive accumulation of collagen which contains increased levels of pyridinoline cross-links." | 3.72 | Increased formation of pyridinoline cross-links due to higher telopeptide lysyl hydroxylase levels is a general fibrotic phenomenon. ( Bank, RA; Boers, W; DeGroot, J; Huizinga, TW; Karel Ronday, H; Middelkoop, E; Ulrich, MM; van den Bogaerdt, AJ; van der Slot, AJ; Zuurmond, AM, 2004) |
| "Diseases such as uterine leiomyomata (fibroids and benign tumors of the uterus) and keloids (raised scars) may share common etiology." | 3.01 | Uterine leiomyomata and keloids fibrosis origins: a mini-review of fibroproliferative diseases. ( Edwards, TL; Hampton, G; Hellwege, JN; Kim, J; Velez Edwards, DR, 2023) |
| "Keloids and hypertrophic scars are pathological cutaneous scars." | 2.82 | Role of Inflammasomes in Keloids and Hypertrophic Scars-Lessons Learned from Chronic Diabetic Wounds and Skin Fibrosis. ( Huang, C; Ogawa, R, 2022) |
| "Scars are generated in mature skin as a result of the normal repair process, but the replacement of normal tissue with scar tissue can lead to biomechanical and functional deficiencies in the skin as well as psychological and social issues for patients that negatively affect quality of life." | 2.66 | A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis. ( Bayat, A; Ud-Din, S; Wilgus, TA, 2020) |
| "Fibrosis is a common pathological state characterized by the excessive accumulation of extracellular matrix components, but the pathogenesis of the disease is still not clear." | 2.55 | MicroRNA-29: A Crucial Player in Fibrotic Disease. ( Deng, Z; He, L; He, Y; Lu, L; Shi, A; Shi, H; Yang, X, 2017) |
| "Skin fibrosis is a common pathological process characterized by fibroblast proliferation and excessive deposition of extracellular matrix." | 2.55 | MicroRNA-21 in Skin Fibrosis: Potential for Diagnosis and Treatment. ( Chen, T; Lei, Y; Li, Y; Lyu, L; Zhang, J; Zuo, R, 2017) |
| "The etiology of keloids is unknown but they occur after dermal injury in genetically susceptible individuals, and they cause both physical and psychological distress for the affected individuals." | 2.53 | Keloids: The paradigm of skin fibrosis - Pathomechanisms and treatment. ( Andrews, JP; Macarak, E; Marttala, J; Rosenbloom, J; Uitto, J, 2016) |
| "Organ fibrosis has been viewed as one of the major medical problems, which can lead to progressive dysfunction of the liver, lung, kidney, skin, heart, and eventually death of patients." | 2.48 | Organ fibrosis inhibited by blocking transforming growth factor-β signaling via peroxisome proliferator-activated receptor γ agonists. ( Cheng, NS; Deng, YL; Xiong, XZ, 2012) |
| "The medical subject headings ''scarring'' were combined with ''mechanisms''." | 2.48 | An overview of biological basis of pathologic scarring. ( Adeyemo, WL; Mofikoya, BO; Ugburo, AO, 2012) |
| "Fibroproliferative scars remain an ongoing clinical challenge." | 2.42 | Fibroproliferative scars. ( Garner, WL; Rahban, SR, 2003) |
| " Other elastin deficiencies may be due to excess elastolysis or gene dosage effects." | 2.39 | Regulation of elastin synthesis in pathological states. ( Davidson, JM; Giro, MG; Zang, MC; Zoia, O, 1995) |
| "Skin fibrosis is a common pathological manifestation in systemic sclerosis (SSc), keloid, and localized scleroderma (LS) characterized by fibroblast activation and excessive extracellular matrix (ECM) deposition." | 1.91 | Enhancement of Zyxin Promotes Skin Fibrosis by Regulating FAK/PI3K/AKT and TGF-β Signaling Pathways via Integrins. ( Gong, Y; Huang, Y; Jiang, S; Lin, J; Liu, J; Liu, Q; Ma, Y; Pu, W; Shi, X; Tang, Y; Wang, J; Wu, W; Zhang, Y; Zhao, H, 2023) |
| "Fibrosis is a common pathophysiological response of many tissues and organs subjected to chronic injury." | 1.72 | Skin fibrosis associated with keloid, scleroderma and Jorge Lobo's disease (lacaziosis): An immuno-histochemical study. ( Kanashiro-Galo, L; Mosser, DM; Pagliari, C; Quaresma, JAS; Silva, AMG; Sotto, MN; Tafuri, WL; Tomokane, TY, 2022) |
| "Skin fibrosis is a hallmark of a wide array of dermatological diseases which can greatly impact the patients' quality of life." | 1.72 | Increased Expression of Galectin-3 in Skin Fibrosis: Evidence from In Vitro and In Vivo Studies. ( Almudéver, P; Alonso-Carpio, M; Cortijo, J; Marín, S; Milara, J; Montero, P; Peiró, T; Ribera, P; Roger, I, 2022) |
| "Keloids are a benign dermal fibrotic disorder with features similar to malignant tumors." | 1.72 | Single-Cell RNA-Sequencing Reveals Lineage-Specific Regulatory Changes of Fibroblasts and Vascular Endothelial Cells in Keloids. ( Chen, J; Chen, W; Li, Z; Liu, X; Long, X; Ma, B; Meng, T; Yu, N; Zeng, Q; Zhou, Z, 2022) |
| "Keloid specimens and grossly normal scars were excised, and local expression of CXCL12 was assayed." | 1.62 | Systemic Fibrocyte Levels and Keloid Expression of the Chemoattractant CXCL12 Are Upregulated Compared With Patients With Normal Scar. ( Burdick, MD; Campbell, CA; Strieter, RM, 2021) |
| "Keloid and hypertrophic scars are skin fibrosis-associated disorders that exhibit an uncontrollable proliferation of fibroblasts and their subsequent contribution to the excessive accumulation of extracellular matrix (ECM) in the dermis." | 1.62 | Ameliorating Fibrotic Phenotypes of Keloid Dermal Fibroblasts through an Epidermal Growth Factor-Mediated Extracellular Matrix Remodeling. ( Anggradita, LD; Bae, J; Hur, SS; Hwang, NS; Hwang, Y; Kim, H; Lee, SJ; Nam, SM, 2021) |
| "Keloids are characterized by increased deposition of fibrous tissue in the skin and subcutaneous tissue following an abnormal wound healing process." | 1.62 | Halofuginone regulates keloid fibroblast fibrotic response to TGF-β induction. ( Chatelain, B; Dirand, Z; Humbert, P; Isidoro, C; Lihoreau, T; Marty, P; Rolin, G; Secomandi, E; Senez, C; Tissot, M, 2021) |
| "A keloid is a type of pathological scar often caused by abnormal tissue repair after a skin injury and is more common in genetically susceptible individuals." | 1.62 | Downregulation of Epac Reduces Fibrosis and Induces Apoptosis Through Akt Signaling in Human Keloid Fibroblasts. ( Bao, X; Feng, Y; Liu, S; Lv, W; Ren, Y; Yi, Z; Zhang, Q, 2021) |
| "Keloid is a benign dermal tumor with excessive hyperplasia and deposition of collagen." | 1.56 | Overexpression of miR-133a-3p inhibits fibrosis and proliferation of keloid fibroblasts by regulating IRF5 to inhibit the TGF-β/Smad2 pathway. ( Huang, Y; Jiang, L; Lin, L; Liu, J; Wang, P; Wang, X; Wang, Y, 2020) |
| "Visnagin is a furanochromone and one of the main compounds of Ammi visnaga L." | 1.56 | Visnagin ameliorates myocardial ischemia/reperfusion injury through the promotion of autophagy and the inhibition of apoptosis. ( Feng, BB; Fu, HR; Li, XS; Pan, LH; Zhang, YH, 2020) |
| "Paclitaxel (PTX) was an effective chemotherapeutic agent and has been reported to have anti-fibrotic effects, but the strong hydrophobicity brings a challenge for its clinical application." | 1.51 | Improving the anti-keloid outcomes through liposomes loading paclitaxel-cholesterol complexes. ( Chen, L; Gao, Z; Huang, W; Jin, M; Jin, Z; Wang, M; Wang, Q, 2019) |
| "Ginsenoside Rg3 (Rg3) has been reported to exert numerous antitumor effects, thus indicating that Rg3 may be a potential therapeutic agent that targets keloids." | 1.48 | Ginsenoside Rg3 inhibits keloid fibroblast proliferation, angiogenesis and collagen synthesis in vitro via the TGF‑β/Smad and ERK signaling pathways. ( Bian, W; Cheng, L; Jin, R; Tang, M; Wang, W; Zhang, L; Zhang, Y, 2018) |
| "Keloids are wounding-induced tumor-like human scars." | 1.43 | Keloid-derived, plasma/fibrin-based skin equivalents generate de novo dermal and epidermal pathology of keloid fibrosis in a mouse model. ( Benya, PD; Chiu, WC; Choi, A; Hsu, T; Kim, EW; Kulber, DA; Lee, YS; Sarkozy, H; Tuan, TL, 2016) |
| "Polyfibromatosis is a rare fibrosing condition characterized by fibromatosis in different body areas and by keloid formation, and which can be associated with arthropathy and osteolysis." | 1.39 | Arthropathy, osteolysis, keloids, relapsing conjunctival pannus and gingival overgrowth: a variant of polyfibromatosis? ( Cinotti, E; Di Maria, E; Faravelli, F; Ferrero, G; Papadia, M; Paparo, F; Rongioletti, F; Traverso, C, 2013) |
| "This pathological scar formation is often associates with pain and malfunction of the organ." | 1.38 | Characterization of oral ulcer and pathological scar in nude mice model. ( Amiranashvili, I; Gogilashvili, Q; Imnadze, I; Sukhitashvili, N; Tabaghua, G, 2012) |
| "Keloids and hypertrophic scars are significant symptomatic clinical problems characterized by the excessive and abnormal deposition of collagen-based extracellular matrix (ECM) components." | 1.37 | Smad interacting protein 1 as a regulator of skin fibrosis in pathological scars. ( Bai, XZ; Cai, WX; Hu, DH; Liu, JQ; Shi, JH; Tang, CW; Wang, HT; Zhang, YG; Zhang, ZF; Zhao, ZT; Zhu, HY, 2011) |
| "Atypical fibroxanthoma (AFX) with prominent fibrosis, sclerosis and hyalinization, and near-total tumor regression is rare." | 1.36 | The histopathologic spectrum of regression in atypical fibroxanthoma. ( Calonje, JE; Robson, A; Stefanato, CM, 2010) |
| "Keloids are benign dermal tumors that form during wound healing in genetically susceptible individuals." | 1.36 | Epigenetically altered wound healing in keloid fibroblasts. ( Broquist, AH; Gayden, AE; Nanney, LB; Opalenik, SR; Raju, L; Russell, JD; Russell, SB; Trupin, KM; Williams, SM, 2010) |
| "Keloids are benign tumors of the dermis that form during a protracted wound healing process." | 1.35 | Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. ( Boone, BE; Opalenik, SR; Russell, SB; Smith, JC; Williams, SM, 2008) |
| "Fibrosis is a major cause of human death and disability." | 1.34 | Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease? ( Karasek, MA, 2007) |
| "Keloid is a fibrotic skin disorder that results in an excessive deposition of extracellular matrix, which is associated with altered-expression of or -responses to TGF-beta in dermal fibroblasts." | 1.32 | IFN-gamma fails to antagonize fibrotic effect of TGF-beta on keloid-derived dermal fibroblasts. ( Hasegawa, T; Nakao, A; Ogawa, H; Sumiyoshi, K; Tsuboi, R, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (6.90) | 18.2507 |
| 2000's | 13 (14.94) | 29.6817 |
| 2010's | 39 (44.83) | 24.3611 |
| 2020's | 29 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, HR | 1 |
| Li, XS | 1 |
| Zhang, YH | 1 |
| Feng, BB | 1 |
| Pan, LH | 1 |
| Hua, Z | 1 |
| Wei, P | 1 |
| Dong, X | 2 |
| Jin, X | 1 |
| Li, Y | 3 |
| Li, M | 1 |
| Qu, C | 1 |
| Tang, Z | 1 |
| Zhou, Z | 2 |
| Yu, Z | 1 |
| Wang, X | 2 |
| Xin, L | 1 |
| Shi, T | 1 |
| Hermenean, A | 1 |
| Oatis, D | 1 |
| Herman, H | 1 |
| Ciceu, A | 1 |
| D'Amico, G | 1 |
| Trotta, MC | 1 |
| Huang, C | 1 |
| Ogawa, R | 2 |
| Tafuri, WL | 1 |
| Tomokane, TY | 1 |
| Silva, AMG | 1 |
| Kanashiro-Galo, L | 1 |
| Mosser, DM | 1 |
| Quaresma, JAS | 1 |
| Pagliari, C | 1 |
| Sotto, MN | 1 |
| Cohen, AJ | 3 |
| Nikbakht, N | 3 |
| Uitto, J | 7 |
| Peiró, T | 2 |
| Alonso-Carpio, M | 2 |
| Ribera, P | 2 |
| Almudéver, P | 2 |
| Roger, I | 2 |
| Montero, P | 2 |
| Marín, S | 2 |
| Milara, J | 2 |
| Cortijo, J | 2 |
| Kidzeru, EB | 1 |
| Lebeko, M | 1 |
| Sharma, JR | 1 |
| Nkengazong, L | 1 |
| Adeola, HA | 1 |
| Ndlovu, H | 1 |
| P Khumalo, N | 1 |
| Bayat, A | 6 |
| Dolivo, DM | 1 |
| Sun, LS | 1 |
| Rodrigues, AE | 1 |
| Galiano, RD | 2 |
| Mustoe, TA | 2 |
| Hong, SJ | 2 |
| Huang, Y | 2 |
| Zhao, H | 1 |
| Zhang, Y | 2 |
| Tang, Y | 1 |
| Shi, X | 1 |
| Jiang, S | 1 |
| Pu, W | 1 |
| Liu, J | 3 |
| Ma, Y | 1 |
| Lin, J | 2 |
| Wu, W | 1 |
| Gong, Y | 1 |
| Wang, J | 1 |
| Liu, Q | 1 |
| Hampton, G | 1 |
| Kim, J | 1 |
| Edwards, TL | 1 |
| Hellwege, JN | 1 |
| Velez Edwards, DR | 1 |
| Faour, S | 1 |
| Farahat, M | 1 |
| Aijaz, A | 1 |
| Jeschke, MG | 2 |
| Wood, FM | 1 |
| Middelkoop, E | 2 |
| Teot, L | 1 |
| Gauglitz, GG | 1 |
| Jeon, YR | 1 |
| Roh, H | 2 |
| Jung, JH | 1 |
| Ahn, HM | 3 |
| Lee, JH | 2 |
| Yun, CO | 4 |
| Lee, WJ | 4 |
| Wang, Y | 1 |
| Lin, L | 1 |
| Wang, P | 1 |
| Jiang, L | 1 |
| Uchiyama, M | 1 |
| Harada, K | 1 |
| Tobita, R | 1 |
| Irisawa, R | 1 |
| Tsuboi, R | 2 |
| Darmawan, CC | 1 |
| Montenegro, SE | 1 |
| Jo, G | 1 |
| Kusumaningrum, N | 1 |
| Lee, SH | 1 |
| Chung, JH | 1 |
| Mun, JH | 1 |
| Liu, P | 1 |
| Hu, Y | 1 |
| Xia, L | 1 |
| DU, M | 1 |
| Hu, Z | 1 |
| Russo, B | 1 |
| Brembilla, NC | 1 |
| Chizzolini, C | 1 |
| Lv, W | 1 |
| Liu, S | 1 |
| Zhang, Q | 2 |
| Yi, Z | 1 |
| Bao, X | 1 |
| Feng, Y | 1 |
| Ren, Y | 1 |
| Jeon, HB | 1 |
| Roh, TS | 1 |
| Wilgus, TA | 1 |
| Ud-Din, S | 1 |
| Marty, P | 1 |
| Chatelain, B | 1 |
| Lihoreau, T | 1 |
| Tissot, M | 1 |
| Dirand, Z | 1 |
| Humbert, P | 1 |
| Senez, C | 1 |
| Secomandi, E | 1 |
| Isidoro, C | 1 |
| Rolin, G | 1 |
| Kim, H | 1 |
| Anggradita, LD | 1 |
| Lee, SJ | 1 |
| Hur, SS | 1 |
| Bae, J | 1 |
| Hwang, NS | 1 |
| Nam, SM | 1 |
| Hwang, Y | 1 |
| Norouzi-Barough, L | 1 |
| Liu, X | 1 |
| Chen, W | 1 |
| Zeng, Q | 1 |
| Ma, B | 2 |
| Li, Z | 1 |
| Meng, T | 1 |
| Chen, J | 1 |
| Yu, N | 1 |
| Long, X | 1 |
| Campbell, CA | 1 |
| Burdick, MD | 1 |
| Strieter, RM | 1 |
| Li, X | 4 |
| Zhai, Y | 1 |
| Xi, B | 1 |
| Ma, W | 1 |
| Zhang, J | 3 |
| Ma, X | 1 |
| Miao, Y | 1 |
| Zhao, Y | 1 |
| Ning, W | 1 |
| Zhou, H | 1 |
| Yang, C | 1 |
| Lei, Y | 1 |
| Lyu, L | 1 |
| Zuo, R | 1 |
| Chen, T | 1 |
| Na, Y | 1 |
| Wadhwa, R | 1 |
| Hong, J | 1 |
| Ren, J | 1 |
| Su, L | 1 |
| Cheng, S | 1 |
| Zhou, J | 1 |
| Ye, X | 1 |
| Dong, Y | 1 |
| Sun, S | 1 |
| Qi, F | 1 |
| Liu, Z | 2 |
| Pleat, J | 1 |
| Zhai, H | 1 |
| Zhu, N | 1 |
| Tang, M | 1 |
| Bian, W | 1 |
| Cheng, L | 1 |
| Zhang, L | 2 |
| Jin, R | 1 |
| Wang, W | 1 |
| Song, CL | 1 |
| Yao, M | 1 |
| Coentro, JQ | 1 |
| Pugliese, E | 1 |
| Hanley, G | 1 |
| Raghunath, M | 1 |
| Zeugolis, DI | 1 |
| Ho, JD | 1 |
| Chung, HJ | 2 |
| Ms Barron, A | 1 |
| Ho, DA | 1 |
| Sahni, D | 1 |
| Browning, JL | 1 |
| Bhawan, J | 1 |
| Han, B | 1 |
| Fan, J | 1 |
| Liu, L | 1 |
| Tian, J | 1 |
| Gan, C | 1 |
| Yang, Z | 1 |
| Jiao, H | 1 |
| Zhang, T | 1 |
| Zhang, H | 1 |
| Shook, BA | 1 |
| Wasko, RR | 1 |
| Rivera-Gonzalez, GC | 1 |
| Salazar-Gatzimas, E | 1 |
| López-Giráldez, F | 1 |
| Dash, BC | 1 |
| Muñoz-Rojas, AR | 1 |
| Aultman, KD | 1 |
| Zwick, RK | 1 |
| Lei, V | 1 |
| Arbiser, JL | 1 |
| Miller-Jensen, K | 1 |
| Clark, DA | 1 |
| Hsia, HC | 1 |
| Horsley, V | 1 |
| Chen, Z | 1 |
| Wang, H | 1 |
| Huguier, V | 1 |
| Giot, JP | 1 |
| Simonneau, M | 1 |
| Levillain, P | 1 |
| Charreau, S | 1 |
| Garcia, M | 1 |
| Jégou, JF | 1 |
| Bodet, C | 1 |
| Morel, F | 1 |
| Lecron, JC | 1 |
| Favot, L | 1 |
| Wang, M | 1 |
| Chen, L | 1 |
| Huang, W | 1 |
| Jin, M | 1 |
| Wang, Q | 1 |
| Gao, Z | 1 |
| Jin, Z | 1 |
| Cinotti, E | 1 |
| Ferrero, G | 1 |
| Paparo, F | 1 |
| Papadia, M | 1 |
| Faravelli, F | 1 |
| Rongioletti, F | 1 |
| Traverso, C | 1 |
| Di Maria, E | 1 |
| Theoret, CL | 1 |
| Olutoye, OO | 1 |
| Parnell, LK | 1 |
| Hicks, J | 1 |
| Zhang, GY | 3 |
| Wu, LC | 1 |
| Dai, T | 1 |
| Chen, SY | 1 |
| Wang, AY | 2 |
| Lin, K | 1 |
| Lin, DM | 1 |
| Yang, JQ | 1 |
| Cheng, B | 1 |
| Gao, WY | 3 |
| Li, ZJ | 2 |
| Zhang, C | 1 |
| Ma, S | 1 |
| Wen, H | 1 |
| Lee, YS | 1 |
| Hsu, T | 1 |
| Chiu, WC | 1 |
| Sarkozy, H | 1 |
| Kulber, DA | 1 |
| Choi, A | 1 |
| Kim, EW | 1 |
| Benya, PD | 1 |
| Tuan, TL | 1 |
| Marttala, J | 2 |
| Andrews, JP | 2 |
| Rosenbloom, J | 2 |
| Macarak, E | 1 |
| Jumper, N | 1 |
| Hodgkinson, T | 1 |
| Arscott, G | 1 |
| Har-Shai, Y | 1 |
| Paus, R | 1 |
| Zhao, J | 1 |
| Zhong, A | 1 |
| Friedrich, EE | 1 |
| Jia, S | 1 |
| Xie, P | 1 |
| Zhao, B | 1 |
| Guan, H | 1 |
| Liu, JQ | 2 |
| Zheng, Z | 1 |
| Zhou, Q | 1 |
| Su, LL | 1 |
| Hu, DH | 2 |
| Deng, Z | 1 |
| He, Y | 1 |
| Yang, X | 1 |
| Shi, H | 1 |
| Shi, A | 1 |
| Lu, L | 1 |
| He, L | 1 |
| Steplewski, A | 1 |
| Chung, KY | 1 |
| Fertala, A | 1 |
| Lopes, LB | 1 |
| Furnish, EJ | 1 |
| Komalavilas, P | 1 |
| Flynn, CR | 1 |
| Ashby, P | 1 |
| Hansen, A | 1 |
| Ly, DP | 1 |
| Yang, GP | 1 |
| Longaker, MT | 1 |
| Panitch, A | 1 |
| Brophy, CM | 1 |
| Yi, CG | 1 |
| Chen, XL | 1 |
| Guo, SZ | 1 |
| Gragnani, A | 1 |
| Warde, M | 1 |
| Furtado, F | 1 |
| Ferreira, LM | 1 |
| Stefanato, CM | 1 |
| Robson, A | 1 |
| Calonje, JE | 1 |
| Valand, K | 1 |
| McLoughlin, PM | 1 |
| Russell, SB | 2 |
| Russell, JD | 1 |
| Trupin, KM | 1 |
| Gayden, AE | 1 |
| Opalenik, SR | 2 |
| Nanney, LB | 1 |
| Broquist, AH | 1 |
| Raju, L | 1 |
| Williams, SM | 2 |
| Kronenberg, D | 1 |
| Bruns, BC | 1 |
| Moali, C | 1 |
| Vadon-Le Goff, S | 1 |
| Sterchi, EE | 1 |
| Traupe, H | 1 |
| Böhm, M | 1 |
| Hulmes, DJ | 1 |
| Stöcker, W | 1 |
| Becker-Pauly, C | 1 |
| McCarty, SM | 1 |
| Syed, F | 1 |
| Zhang, ZF | 1 |
| Zhang, YG | 1 |
| Shi, JH | 1 |
| Zhao, ZT | 1 |
| Wang, HT | 1 |
| Bai, XZ | 1 |
| Cai, WX | 1 |
| Zhu, HY | 1 |
| Tang, CW | 1 |
| Pistorio, AL | 1 |
| Ehrlich, HP | 1 |
| Yu, Q | 1 |
| Cheng, T | 1 |
| Liao, T | 1 |
| Nie, CL | 1 |
| Zheng, X | 1 |
| Xie, XG | 1 |
| Albers, AE | 1 |
| Kim, YO | 1 |
| Choi, IK | 1 |
| Rah, DK | 1 |
| Mofikoya, BO | 1 |
| Adeyemo, WL | 1 |
| Ugburo, AO | 1 |
| Sukhitashvili, N | 1 |
| Imnadze, I | 1 |
| Tabaghua, G | 1 |
| Gogilashvili, Q | 1 |
| Amiranashvili, I | 1 |
| Jin, SE | 1 |
| Kim, CK | 1 |
| Kim, YB | 1 |
| Deng, YL | 1 |
| Xiong, XZ | 1 |
| Cheng, NS | 1 |
| Canady, J | 1 |
| Arndt, S | 1 |
| Karrer, S | 1 |
| Bosserhoff, AK | 1 |
| Rahban, SR | 1 |
| Garner, WL | 1 |
| Hasegawa, T | 1 |
| Nakao, A | 1 |
| Sumiyoshi, K | 1 |
| Ogawa, H | 1 |
| Barzilai, A | 1 |
| Lyakhovitsky, A | 1 |
| Horowitz, A | 1 |
| Trau, H | 1 |
| Labandeira, J | 2 |
| León-Mateos, A | 2 |
| Suárez-Peñaranda, JM | 2 |
| Garea, MT | 2 |
| Toribio, J | 2 |
| Le, AD | 1 |
| Wu, Y | 1 |
| Messadi, DV | 1 |
| Akhondzadeh, A | 1 |
| Nguyen, AL | 1 |
| Aghaloo, TL | 1 |
| Kelly, AP | 1 |
| Bertolami, CN | 1 |
| van der Slot, AJ | 1 |
| Zuurmond, AM | 1 |
| van den Bogaerdt, AJ | 1 |
| Ulrich, MM | 1 |
| Boers, W | 1 |
| Karel Ronday, H | 1 |
| DeGroot, J | 1 |
| Huizinga, TW | 1 |
| Bank, RA | 1 |
| Karasek, MA | 1 |
| Thielitz, A | 1 |
| Vetter, RW | 1 |
| Schultze, B | 1 |
| Wrenger, S | 1 |
| Simeoni, L | 1 |
| Ansorge, S | 1 |
| Neubert, K | 1 |
| Faust, J | 1 |
| Lindenlaub, P | 1 |
| Gollnick, HP | 1 |
| Reinhold, D | 1 |
| Smith, JC | 1 |
| Boone, BE | 1 |
| Davidson, JM | 1 |
| Zang, MC | 1 |
| Zoia, O | 1 |
| Giro, MG | 1 |
| Igarashi, A | 1 |
| Nashiro, K | 1 |
| Kikuchi, K | 1 |
| Sato, S | 1 |
| Ihn, H | 1 |
| Fujimoto, M | 1 |
| Grotendorst, GR | 1 |
| Takehara, K | 1 |
| Varga, J | 1 |
| Kähäri, VM | 1 |
| Burkhart, CG | 1 |
| Burkhart, CN | 1 |
| Higgins, PJ | 1 |
| Slack, JK | 1 |
| Diegelmann, RF | 1 |
| Staiano-Coico, L | 1 |
| Sollberg, S | 1 |
| Peltonen, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of a Filming Formulation of Hydrogen Peroxide and Hyaluronic Acid (BMG0703) in Promoting the Healing of Post-extraction Sites, Compared to Placebo and 0.2% Chlorhexidine. A Randomised Controlled Clinical Trial.[NCT04438434] | Phase 3 | 57 participants (Anticipated) | Interventional | 2020-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 reviews available for khellin and Cirrhosis
| Article | Year |
|---|---|
Galectin 1-A Key Player between Tissue Repair and Fibrosis.
Topics: Fibrosis; Galectin 1; Humans; Keloid; Phosphatidylinositol 3-Kinases; Wound Healing | 2022 |
Role of Inflammasomes in Keloids and Hypertrophic Scars-Lessons Learned from Chronic Diabetic Wounds and Skin Fibrosis.
Topics: Cicatrix, Hypertrophic; Diabetes Mellitus; Endothelial Cells; Fibrosis; Humans; Inflammasomes; Infla | 2022 |
Keloid Disorder: Genetic Basis, Gene Expression Profiles, and Immunological Modulation of the Fibrotic Processes in the Skin.
Topics: Cell Proliferation; Collagen; Fibronectins; Fibrosis; Humans; Keloid; Skin; Transcriptome | 2023 |
Keloid Disorder: Genetic Basis, Gene Expression Profiles, and Immunological Modulation of the Fibrotic Processes in the Skin.
Topics: Cell Proliferation; Collagen; Fibronectins; Fibrosis; Humans; Keloid; Skin; Transcriptome | 2023 |
Keloid Disorder: Genetic Basis, Gene Expression Profiles, and Immunological Modulation of the Fibrotic Processes in the Skin.
Topics: Cell Proliferation; Collagen; Fibronectins; Fibrosis; Humans; Keloid; Skin; Transcriptome | 2023 |
Keloid Disorder: Genetic Basis, Gene Expression Profiles, and Immunological Modulation of the Fibrotic Processes in the Skin.
Topics: Cell Proliferation; Collagen; Fibronectins; Fibrosis; Humans; Keloid; Skin; Transcriptome | 2023 |
Keloid Disorder: Genetic Basis, Gene Expression Profiles, and Immunological Modulation of the Fibrotic Processes in the Skin.
Topics: Cell Proliferation; Collagen; Fibronectins; Fibrosis; Humans; Keloid; Skin; Transcriptome | 2023 |
Keloid Disorder: Genetic Basis, Gene Expression Profiles, and Immunological Modulation of the Fibrotic Processes in the Skin.
Topics: Cell Proliferation; Collagen; Fibronectins; Fibrosis; Humans; Keloid; Skin; Transcriptome | 2023 |
Keloid Disorder: Genetic Basis, Gene Expression Profiles, and Immunological Modulation of the Fibrotic Processes in the Skin.
Topics: Cell Proliferation; Collagen; Fibronectins; Fibrosis; Humans; Keloid; Skin; Transcriptome | 2023 |
Keloid Disorder: Genetic Basis, Gene Expression Profiles, and Immunological Modulation of the Fibrotic Processes in the Skin.
Topics: Cell Proliferation; Collagen; Fibronectins; Fibrosis; Humans; Keloid; Skin; Transcriptome | 2023 |
Keloid Disorder: Genetic Basis, Gene Expression Profiles, and Immunological Modulation of the Fibrotic Processes in the Skin.
Topics: Cell Proliferation; Collagen; Fibronectins; Fibrosis; Humans; Keloid; Skin; Transcriptome | 2023 |
Immune cells and associated molecular markers in dermal fibrosis with focus on raised cutaneous scars.
Topics: Cicatrix, Hypertrophic; Cytokines; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Keloid | 2023 |
Epidermal Potentiation of Dermal Fibrosis: Lessons from Occlusion and Mucosal Healing.
Topics: Cicatrix, Hypertrophic; Epidermis; Fibrosis; Humans; Keloid; Skin; Wound Healing | 2023 |
Uterine leiomyomata and keloids fibrosis origins: a mini-review of fibroproliferative diseases.
Topics: Female; Fibrosis; Humans; Keloid; Leiomyoma; Uterus | 2023 |
Fibrosis in burns: an overview of mechanisms and therapies.
Topics: Burns; Fibrosis; Humans; Keloid; Quality of Life; Skin | 2023 |
Scars.
Topics: Cicatrix, Hypertrophic; Fibrosis; Humans; Keloid; Skin; Wound Healing | 2023 |
Interplay Between Keratinocytes and Fibroblasts: A Systematic Review Providing a New Angle for Understanding Skin Fibrotic Disorders.
Topics: Animals; Cicatrix, Hypertrophic; Fibroblasts; Fibrosis; Humans; Keloid; Keratinocytes; Scleroderma, | 2020 |
A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis.
Topics: Animals; Biomarkers; Cell Communication; Cicatrix; Cicatrix, Hypertrophic; Disease Models, Animal; D | 2020 |
Validation strategies for identifying drug targets in dermal fibrotic disorders.
Topics: Animals; Drug Development; Drug Discovery; Fibrosis; Humans; Keloid; Molecular Targeted Therapy; Ski | 2021 |
MicroRNA-21 in Skin Fibrosis: Potential for Diagnosis and Treatment.
Topics: Cicatrix, Hypertrophic; Fibrosis; Gene Expression Regulation; Humans; Keloid; MicroRNAs; Molecular T | 2017 |
[Advances in the research of relationship between CD26 and hypertrophic scar and keloid].
Topics: Cicatrix, Hypertrophic; Dipeptidyl Peptidase 4; Fibrosis; Humans; Keloid | 2018 |
Current and upcoming therapies to modulate skin scarring and fibrosis.
Topics: Animals; Cicatrix, Hypertrophic; Fibrosis; Humans; Inflammation; Keloid; Skin Diseases | 2019 |
Keloids: Animal models and pathologic equivalents to study tissue fibrosis.
Topics: Animals; Cicatrix, Hypertrophic; Disease Models, Animal; Fibroblasts; Fibrosis; Humans; Keloid; Mice | 2016 |
Keloids: The paradigm of skin fibrosis - Pathomechanisms and treatment.
Topics: Collagen; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Keloid; Skin; Steroids; Wound Healing | 2016 |
MicroRNA-29: A Crucial Player in Fibrotic Disease.
Topics: Fibrosis; Gene Expression Regulation; Humans; Keloid; Kidney; Liver Cirrhosis; MicroRNAs; Myocardium | 2017 |
Influence of the human leukocyte antigen complex on the development of cutaneous fibrosis: an immunogenetic perspective.
Topics: Cicatrix, Hypertrophic; Connective Tissue Diseases; Evidence-Based Medicine; Fibrosis; HLA Antigens; | 2010 |
An overview of biological basis of pathologic scarring.
Topics: Cicatrix; Cytokines; Fibrosis; Humans; Inflammation; Keloid; Skin; Skin Physiological Phenomena; Tra | 2012 |
Organ fibrosis inhibited by blocking transforming growth factor-β signaling via peroxisome proliferator-activated receptor γ agonists.
Topics: Epithelial-Mesenchymal Transition; Fibrosis; Humans; Keloid; Kidney; Liver Cirrhosis; Myocardium; PP | 2012 |
Fibroproliferative scars.
Topics: Cicatrix; Cicatrix, Hypertrophic; Fibrosis; Humans; Keloid; Wound Healing | 2003 |
Elevated vascular endothelial growth factor in keloids: relevance to tissue fibrosis.
Topics: DNA-Binding Proteins; Endothelial Cells; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Hypoxi | 2004 |
Regulation of elastin synthesis in pathological states.
Topics: Animals; Cutis Laxa; Elastin; Fibrosis; Humans; Keloid; Progeria | 1995 |
Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders.
Topics: Colonic Diseases; Eosinophilia; Eosinophilia-Myalgia Syndrome; Fasciitis; Fibrosis; Humans; Keloid; | 1997 |
63 other studies available for khellin and Cirrhosis
| Article | Year |
|---|---|
Visnagin ameliorates myocardial ischemia/reperfusion injury through the promotion of autophagy and the inhibition of apoptosis.
Topics: Animals; Apoptosis; Autophagy; Cardiotonic Agents; Fibrosis; Khellin; Male; Myocardial Reperfusion I | 2020 |
Letter to the Editor: Comment on Jeon HB, et al. Metformin Inhibits Transforming Growth Factor β-Induced Fibrogenic Response of Human Dermal Fibroblasts and Suppresses Fibrosis in Keloid Spheroids ( Ann Plast Surg . 2021;86:406-411).
Topics: Cells, Cultured; Fibroblasts; Fibrosis; Humans; Keloid; Metformin; Transforming Growth Factor beta; | 2022 |
Letter to the Editor: Comment on Jeon HB, et al. Metformin Inhibits Transforming Growth Factor β-Induced Fibrogenic Response of Human Dermal Fibroblasts and Suppresses Fibrosis in Keloid Spheroids ( Ann Plast Surg . 2021;86:406-411).
Topics: Cells, Cultured; Fibroblasts; Fibrosis; Humans; Keloid; Metformin; Transforming Growth Factor beta; | 2022 |
The Polygenic Map of Keloid Fibroblasts Reveals Fibrosis-Associated Gene Alterations in Inflammation and Immune Responses.
Topics: Computational Biology; Disease Susceptibility; Fibroblasts; Fibrosis; Gene Expression Profiling; Gen | 2021 |
Skin fibrosis associated with keloid, scleroderma and Jorge Lobo's disease (lacaziosis): An immuno-histochemical study.
Topics: Endothelial Cells; Fibroblasts; Fibrosis; Forkhead Transcription Factors; Humans; Keloid; Ki-67 Anti | 2022 |
Increased Expression of Galectin-3 in Skin Fibrosis: Evidence from In Vitro and In Vivo Studies.
Topics: Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Galectin 3; Humans; Keloid; Mice; Quality of | 2022 |
Increased Expression of Galectin-3 in Skin Fibrosis: Evidence from In Vitro and In Vivo Studies.
Topics: Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Galectin 3; Humans; Keloid; Mice; Quality of | 2022 |
Increased Expression of Galectin-3 in Skin Fibrosis: Evidence from In Vitro and In Vivo Studies.
Topics: Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Galectin 3; Humans; Keloid; Mice; Quality of | 2022 |
Increased Expression of Galectin-3 in Skin Fibrosis: Evidence from In Vitro and In Vivo Studies.
Topics: Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Galectin 3; Humans; Keloid; Mice; Quality of | 2022 |
Enhancement of Zyxin Promotes Skin Fibrosis by Regulating FAK/PI3K/AKT and TGF-β Signaling Pathways via Integrins.
Topics: Animals; Fibroblasts; Fibrosis; Humans; Integrins; Keloid; Mice; Phosphatidylinositol 3-Kinases; Pro | 2023 |
Antifibrotic Effects of High-Mobility Group Box 1 Protein Inhibitor (Glycyrrhizin) on Keloid Fibroblasts and Keloid Spheroids through Reduction of Autophagy and Induction of Apoptosis.
Topics: Apoptosis; Autophagy; Biomarkers; Cell Survival; Collagen; Extracellular Matrix; Fibroblasts; Fibros | 2019 |
Overexpression of miR-133a-3p inhibits fibrosis and proliferation of keloid fibroblasts by regulating IRF5 to inhibit the TGF-β/Smad2 pathway.
Topics: Adolescent; Adult; Apoptosis; Base Sequence; Biomarkers; Cell Proliferation; Cell Survival; Extracel | 2020 |
Histopathologic and dermoscopic features of 42 cases of folliculitis decalvans: A case series.
Topics: Alopecia; Fibrosis; Folliculitis; Humans; Keloid; Retrospective Studies | 2021 |
Adiponectin-Based Peptide (ADP355) Inhibits Transforming Growth Factor-β1-Induced Fibrosis in Keloids.
Topics: Adiponectin; AMP-Activated Protein Kinase Kinases; Animals; Cell Survival; Cells, Cultured; Cicatrix | 2020 |
miR-4417 suppresses keloid fibrosis growth by inhibiting CyclinD1.
Topics: Apoptosis; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclin D1; Down-Regulation; Fibroblas | 2020 |
Downregulation of Epac Reduces Fibrosis and Induces Apoptosis Through Akt Signaling in Human Keloid Fibroblasts.
Topics: Apoptosis; Cells, Cultured; Dermis; Down-Regulation; Fibroblasts; Fibrosis; Guanine Nucleotide Excha | 2021 |
Metformin Inhibits Transforming Growth Factor β-Induced Fibrogenic Response of Human Dermal Fibroblasts and Suppresses Fibrosis in Keloid Spheroids.
Topics: Cells, Cultured; Fibroblasts; Fibrosis; Humans; Keloid; Metformin; Transforming Growth Factor beta; | 2021 |
Halofuginone regulates keloid fibroblast fibrotic response to TGF-β induction.
Topics: Actins; Adult; Cell Movement; Cell Proliferation; Cells, Cultured; Collagen Type I; Extracellular Ma | 2021 |
Ameliorating Fibrotic Phenotypes of Keloid Dermal Fibroblasts through an Epidermal Growth Factor-Mediated Extracellular Matrix Remodeling.
Topics: Adult; Cell Movement; Cells, Cultured; Cicatrix, Hypertrophic; Elastic Modulus; Enzymes; Epidermal G | 2021 |
Single-Cell RNA-Sequencing Reveals Lineage-Specific Regulatory Changes of Fibroblasts and Vascular Endothelial Cells in Keloids.
Topics: Adult; Carcinogenesis; Cell Differentiation; Cell Lineage; Cells, Cultured; Endothelial Cells; Ephri | 2022 |
Systemic Fibrocyte Levels and Keloid Expression of the Chemoattractant CXCL12 Are Upregulated Compared With Patients With Normal Scar.
Topics: Cell Differentiation; Chemokine CXCL12; Chemotactic Factors; Cicatrix; Fibroblasts; Fibrosis; Humans | 2021 |
Pinocembrin Ameliorates Skin Fibrosis via Inhibiting TGF-β1 Signaling Pathway.
Topics: Animals; Animals, Newborn; Cell Movement; Cell Proliferation; Female; Fibroblasts; Fibrosis; Flavano | 2021 |
Mortalin deficiency suppresses fibrosis and induces apoptosis in keloid spheroids.
Topics: Adenoviridae; Apoptosis; Cell Nucleus; Collagen Type I; Collagen Type III; Elastin; ErbB Receptors; | 2017 |
Human adipose tissue-derived stem cells inhibit the activity of keloid fibroblasts and fibrosis in a keloid model by paracrine signaling.
Topics: Adipose Tissue; Adolescent; Adult; Apoptosis; Cell Movement; Cell Proliferation; Coculture Technique | 2018 |
Ginsenoside Rg3 inhibits keloid fibroblast proliferation, angiogenesis and collagen synthesis in vitro via the TGF‑β/Smad and ERK signaling pathways.
Topics: Adult; Apoptosis; Cell Movement; Cell Proliferation; Collagen; Extracellular Matrix; Female; Fibrobl | 2018 |
Extensive CD34-to-CD90 Fibroblast Transition Defines Regions of Cutaneous Reparative, Hypertrophic, and Keloidal Scarring.
Topics: Actins; Antigens, CD34; Biomarkers; Cicatrix, Hypertrophic; Collagen Type I; Fibroblasts; Fibrosis; | 2019 |
Adipose-derived mesenchymal stem cells treatments for fibroblasts of fibrotic scar via downregulating TGF-β1 and Notch-1 expression enhanced by photobiomodulation therapy.
Topics: Actins; Adipose Tissue; Animals; Apoptosis; Cell Movement; Cell Proliferation; Cicatrix, Hypertrophi | 2019 |
Myofibroblast proliferation and heterogeneity are supported by macrophages during skin repair.
Topics: Adipocytes; Animals; Cell Proliferation; Extracellular Matrix; Fibrosis; Integrin beta1; Keloid; Lec | 2018 |
In vitro analysis of the role of tumor necrosis factor‑stimulated gene‑6 in keloid.
Topics: Adolescent; Adult; Apoptosis; Cell Adhesion Molecules; Cell Cycle Checkpoints; Cell Proliferation; C | 2019 |
Oncostatin M exerts a protective effect against excessive scarring by counteracting the inductive effect of TGFβ1 on fibrosis markers.
Topics: Adult; Biomarkers; Case-Control Studies; Cicatrix, Hypertrophic; Female; Fibroblasts; Fibrosis; Foll | 2019 |
Improving the anti-keloid outcomes through liposomes loading paclitaxel-cholesterol complexes.
Topics: Animals; Apoptosis; Cell Cycle; Cell Proliferation; Cell Survival; Cells, Cultured; Cholesterol; Col | 2019 |
Arthropathy, osteolysis, keloids, relapsing conjunctival pannus and gingival overgrowth: a variant of polyfibromatosis?
Topics: Abnormalities, Multiple; Arthrography; Cleft Palate; Comparative Genomic Hybridization; Conjunctival | 2013 |
Equine exuberant granulation tissue and human keloids: a comparative histopathologic study.
Topics: Animals; Cicatrix, Hypertrophic; Dermis; Epidermis; Fibrosis; Gene Expression Regulation; Horse Dise | 2013 |
NADPH oxidase-2 is a key regulator of human dermal fibroblasts: a potential therapeutic strategy for the treatment of skin fibrosis.
Topics: Cells, Cultured; Collagen; Enzyme Inhibitors; Fibroblasts; Fibrosis; Gene Knockdown Techniques; Huma | 2014 |
Mast cell chymase in keloid induces profibrotic response via transforming growth factor-β1/Smad activation in keloid fibroblasts.
Topics: Adult; Blotting, Western; Chymases; Enzyme-Linked Immunosorbent Assay; Female; Fibroblasts; Fibrosis | 2014 |
Keloid-derived, plasma/fibrin-based skin equivalents generate de novo dermal and epidermal pathology of keloid fibrosis in a mouse model.
Topics: Animals; Cells, Cultured; Collagen Type I; Dermis; Disease Models, Animal; Epidermal Cells; Fibrin; | 2016 |
The Aldo-Keto Reductase AKR1B10 Is Up-Regulated in Keloid Epidermis, Implicating Retinoic Acid Pathway Dysregulation in the Pathogenesis of Keloid Disease.
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Culture Media, Conditioned; Epidermis; Fibroblasts; Fibros | 2016 |
S100A12 Induced in the Epidermis by Reduced Hydration Activates Dermal Fibroblasts and Causes Dermal Fibrosis.
Topics: Animals; Cell Culture Techniques; Cell Line, Tumor; Cicatrix, Hypertrophic; Coculture Techniques; Cu | 2017 |
Hypoxia drives the transition of human dermal fibroblasts to a myofibroblast-like phenotype via the TGF-β1/Smad3 pathway.
Topics: Adult; Cell Hypoxia; Dermis; Fibrosis; Fluorescent Antibody Technique; Humans; Hypoxia-Inducible Fac | 2017 |
Collagen fibril formation. A new target to limit fibrosis.
Topics: Animals; Antibodies, Monoclonal; Bone Morphogenetic Protein 1; Bone Morphogenetic Proteins; Collagen | 2008 |
Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-beta1-induced CTGF expression in keloid fibroblasts.
Topics: 14-3-3 Proteins; Animals; Collagen Type I; Connective Tissue Growth Factor; Cricetinae; Endothelins; | 2009 |
Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts.
Topics: Adolescent; Adult; Blotting, Western; Chromans; Collagen Type I; Female; Fibroblasts; Fibrosis; Huma | 2009 |
Topical tamoxifen therapy in hypertrophic scars or keloids in burns.
Topics: Administration, Topical; Burns; Cell Differentiation; Cell Line; Cell Proliferation; Cicatrix, Hyper | 2010 |
The histopathologic spectrum of regression in atypical fibroxanthoma.
Topics: Aged; Aged, 80 and over; Cheek; Female; Fibrosis; Head and Neck Neoplasms; Histiocytoma, Benign Fibr | 2010 |
Encapsuloma: a case report.
Topics: Aged; Arthroplasty, Replacement; Facial Neuralgia; Female; Fibrosis; Follow-Up Studies; Granuloma, F | 2010 |
Epigenetically altered wound healing in keloid fibroblasts.
Topics: Acetylation; Azacitidine; Black or African American; Cell Division; Cells, Cultured; Culture Media; | 2010 |
Processing of procollagen III by meprins: new players in extracellular matrix assembly?
Topics: Bone Morphogenetic Protein 1; Cells, Cultured; Collagen Type III; Dermis; Extracellular Matrix Prote | 2010 |
Smad interacting protein 1 as a regulator of skin fibrosis in pathological scars.
Topics: Adolescent; Adult; Aged; Child; Cicatrix; Collagen; Collagen Type I; Down-Regulation; Female; Fibrob | 2011 |
Modulatory effects of connexin-43 expression on gap junction intercellular communications with mast cells and fibroblasts.
Topics: Actins; Animals; Cell Culture Techniques; Connexin 43; Fibroblasts; Fibrosis; Gap Junctions; Gene Ex | 2011 |
Role of caveolin-1 in the pathogenesis of tissue fibrosis by keloid-derived fibroblasts in vitro.
Topics: Blotting, Western; Caveolin 1; Cell Survival; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Fi | 2011 |
Adenovirus-relaxin gene therapy for keloids: implication for reversing pathological fibrosis.
Topics: Adenoviridae; Adult; Collagen Type I; Collagen Type III; Enzyme-Linked Immunosorbent Assay; Female; | 2011 |
Characterization of oral ulcer and pathological scar in nude mice model.
Topics: Animals; Cicatrix; Disease Models, Animal; Fibrosis; Humans; Hydrochloric Acid; Immunohistochemistry | 2012 |
Cellular delivery of cationic lipid nanoparticle-based SMAD3 antisense oligonucleotides for the inhibition of collagen production in keloid fibroblasts.
Topics: Cells, Cultured; Collagen Type I; Drug Stability; Drug Storage; Fibroblasts; Fibrosis; Humans; Keloi | 2012 |
Increased KGF expression promotes fibroblast activation in a double paracrine manner resulting in cutaneous fibrosis.
Topics: Cell Communication; Cell Movement; Cell Proliferation; Cells, Cultured; Collagen Type I; Fibroblast | 2013 |
IFN-gamma fails to antagonize fibrotic effect of TGF-beta on keloid-derived dermal fibroblasts.
Topics: Actins; Blotting, Western; Case-Control Studies; Cells, Cultured; Collagen; Collagen Type I; Fibrobl | 2003 |
Keloid-like scleroderma.
Topics: Actins; Elastic Tissue; Female; Fibroblasts; Fibrosis; Humans; Immunohistochemistry; Keloid; Middle | 2003 |
What is nodular-keloidal scleroderma?
Topics: Fibrosis; Humans; Keloid; Scleroderma, Localized; Scleroderma, Systemic; Skin | 2003 |
Polymorphic fibrosing reaction mimicking keloidal scleroderma but without associated classic scleroderma.
Topics: Adult; Female; Fibrosis; Humans; Hyperpigmentation; Keloid; Scleroderma, Localized; Scleroderma, Sys | 2003 |
Increased formation of pyridinoline cross-links due to higher telopeptide lysyl hydroxylase levels is a general fibrotic phenomenon.
Topics: Amino Acids; Cells, Cultured; Cicatrix, Hypertrophic; Dupuytren Contracture; Fascia; Fibrosis; Hand; | 2004 |
Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease?
Topics: Cell Differentiation; Endothelium, Vascular; Fibroblasts; Fibrosis; Humans; Keloid; Microcirculation | 2007 |
Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts.
Topics: Actins; Animals; Collagen Type I; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Diseas | 2008 |
Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways.
Topics: Cells, Cultured; Dermis; Fibroblasts; Fibrosis; Gene Expression Profiling; Humans; Keloid; Oligonucl | 2008 |
Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders.
Topics: Adolescent; Adult; Child; Connective Tissue Growth Factor; Fibrosis; Gene Expression; Growth Substan | 1996 |
Acne keloidalis is lichen simplex chronicus with fibrotic keloidal scarring.
Topics: Acne Keloid; Diagnosis, Differential; Fibrosis; Humans; Keloid; Neck; Neurodermatitis | 1998 |
Differential regulation of PAI-1 gene expression in human fibroblasts predisposed to a fibrotic phenotype.
Topics: Adult; Cell Adhesion; Cells, Cultured; Dermis; Female; Fibroblasts; Fibrosis; Gene Expression Regula | 1999 |
Combined use of in situ hybridization and unlabeled antibody peroxidase anti-peroxidase methods: simultaneous detection of type I procollagen mRNAs and factor VIII-related antigen epitopes in keloid tissue.
Topics: DNA; Epitopes; Factor VIII; Fibrosis; Gene Expression; Humans; Immunoenzyme Techniques; Keloid; Nucl | 1991 |